Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes

Circulation

Volumn 96, Issue 7, 1997, Pages 2397-2406

  Spinale, Francis G ^a   Mukherjee, Rupak ^a   Iannini, Julie P ^a   Whitebread, Steve ^b   Hebbar, Latha ^a   Clair, Mark J ^a   Melton, D Mark ^a   Cox, Montgomery H ^a   Thomas, Patrick B ^a   De Gasparo, Marc ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiotensin; Calcium channels; Cardiovascular disease; Heart failure; Myocardium

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; ENZYME INHIBITION; EXCITATION CONTRACTION COUPLING; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; INOTROPISM; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR DENSITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SARCOLEMMA; STIMULUS RESPONSE; SWINE; TRANSACTIVATION;

EID: 0030868239     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.7.2397     Document Type: Article

References (55)

1. Pieske B, Kretschmann B, Meyer M, Holubarsch C, Weirich J, Posival H, Minami K, Just H, Hasenfuss G. Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation. 1995;92:1169-1178.
2. Davies CH, Davis K, Bennett JG, Pepper JR, Poole-Wilson PA, Harding SE. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation. 1995;92:2540-2549.
3. Hasenfuss G, Mulieri LA, Leavitt B, Allen PD, Haeberle JR, Alpert NR. Alteration of contractile function and excitation-contraction coupling in dilated cardiomyopathy. Circ Res. 1992;70: 1225-1232.
4. Dixon IMC, Lee S-L, Dhalla NS. Nitrendipine binding in congestive heart failure due to myocardial infarction. Circ Res. 1990; 66:782-788.
5. 2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure. J Clin Invest. 1992;90:927-935.
6. 2+ currents of human myocytes from ventricle of non-failing and failing hearts and from atrium. J Mol Cell Cardiol. 1994;26:1307-1320.
7. 2+ exchange activity in cardiomyopathic Syrian hamster. Circ Res. 1994;74:253-261.
8. 2+ transport and mechanics in compensated pressure-overload hypertrophy and congestive heart failure. Circ Res. 1995;77:759-764.
9. Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Psival H, Kuwajima G, Mikoshiba K, Just H, Hasenfuss G. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation. 1995;92:778-784.
10. 2+-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest. 1990;85:305-309.
11. Hart G. Cellular electrophysiology in cardiac hypertropy and failure. Cardiovasc Res. 1994;28:933-946.
12. Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W, Morgan JP. Role of intracellular calcium handling in myocardium from patients with end-stage heart failure caused by ischemic versus dilated cardiomyopathy. Circ Res. 1992;71:18-26.
13. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
14. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
15. Benedict CR, Weiner DH, Johnstone DE, Bourassa MG, Ghali JK, Nicklas J, Kirlin P, Greenberg B, Quinones MA, Yusuf S, for the SOLVD Investigators. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) registry. J Am Coll Cardiol. 1993;22:146A-153A.
16. Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahan S, Kinan D, Howe DM, Kilcoyne L, Metherall J, Benedict C, Yusuf S, Pouleur H, for the SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilation in patients with asymptomatic systolic dysfunction. Circulation. 1993;88:2277-2283.
17. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang C, Kubo SH, Rudin-Toretsky E, Yusef S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction and with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82: 1724-1730.
18. Weinberg EO, Schoen FJ, George D, Kagaya Y, Douglas PS, Litwin SE, Schunkert H, Benedict CR, Lorell BH. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation. 1994;90: 1410-1422.
19. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, Goldstein S. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation. 1994;89:2852-2859.
20. 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation. 1994;90:3034-3046.
21. Kanda T, Araki M, Nakano M, Imai S, Suzuki T, Murata K, Kobayashi I. Chronic effect of losartan in a murine model of dilated cardiomyopathy: comparison with captopril. J Pharmacol Exp Ther. 1995;273:955-958.
22. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Rucinska E, for Losartan Hemodynamic Study Group. Losartan in heart failure: hemodynamic effects and tolerability. Circulation. 1995;91:691-697.
23. 1 receptor subtype. Br J Pharmacol. 1993;110:761-771.
24. 1 receptor antagonist irbesartan in hypertension. Hypertension. 1995;25:22-29.
25. Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, Menard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium depleted normotensives. Circulation. 1995;92:825-834.
26. Spinale FG, de Gasparo M, Whitebread S, Hebbar L, Clair MJ, Melton DM, Krombach RS, Mukherjee R, Iannini JP, O SJ. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing induced heart failure, I: effects on left ventricular performance and neurohormonal systems. Circulation. 1997;96:2385-2396.
27. Spinale FG, Fulbright BM, Mukherjee R, Tanaka R, Hu J, Crawford FA, Zile MR. Relationship between ventricular and myocyte function with tachycardia induced cardiomyopathy. Circ Res. 1992;71:174-187.
28. +-ATPase in tachycardia induced cardiomyopathy. J Mol Cell Cardiol. 1992; 24:277-294.
29. Spinale FG, Holzgrefe HH, Mukherjee R, Hird RB, Walker JD, Arnim-Barker A, Powell JR, Koster WH. Angiotensin converting enzyme inhibition and the progression of congestive cardiomyopathy: effects on left ventricular and myocyte structure and function. Circulation. 1995;92:562-568.
30. Spinale FG, Tempel GE, Mukherjee R, Eble DM, Brown R, Vacchiano C, Zile MR. Cellular and molecular changes in the β-adrenergic receptor system with supraventricular tachycardia induced cardiomyopathy. Cardiovasc Res. 1994;28:1243-1250.
31. Eble DM, Spinale FG. Effects of chronic supraventricular tachycardia on contractile and non-contractile mRNA expression: relation to changes in myocyte structure and function. Am J Physiol. 1995;268:H2426-H2439.
32. Mukherjee R, Hewett KW, Spinale FG. Myocyte electrophysiological properties following the development of supraventricular tachycardia induced cardiomyopathy. J Mol Cell Cardiol. 1995;27: 1333-1348.
33. Zile MR, Mukherjee R, Kato S, Spinale FG. Effects of chronic supraventricular pacing tachycardia on relaxation rate in isolated cardiac muscle cells. Am J Physiol. 1995;268:H2104-H2113.
34. Armstrong PW, Stopps TP, Ford SE, DeBold AJ. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation. 1986;74:1075-1084.
35. Komamura K, Shannon RP, Ihara T, Shen YT, Mirsky I, Bishop SP, Vatner SF. Exhaustion of the Frank-Starling mechanism in conscious dogs with heart failure. Am J Physiol. 1993;265:H1119-H1131.
36. Roth DA, Kazushi U, Helmer GA, Hammond HK. Downregulation of cardiac guanosine 5′-triphosphate binding proteins in right and left ventricle in pacing induced congestive heart failure. J Clin Invest. 1993;91:939-949.
37. Kaab S, Nuss HB, Chiamvimonvat N, O'Rourke B, Pak PH, Kass DA, Marban E, Tomaselli GF. Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing induced heart failure. Circ Res. 1996;78:262-272.
38. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, Stinson EB. β1 and β2 adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1-receptor downregulation in heart failure. Circ Res. 1986;59:297-309.
39. 2+-pump ATPase activity in tachycardia heart failure. Cell Calcium. 1994;16:349-356.
40. 2+-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. Circulation. 1994;90:653-657.
41. 2+ pump and blocking of phospholamban phosphorylation and dephosphorylation by a phospholamban monoclonal antibody. J Biol Chem. 1986;261:7018-7023.
42. Bers DM. Sarcolemmal Ca channels. In: Excitation-Contraction Coupling and Cardiac Contractile Force. Boston, Mass: Kluwer Academic Publishers; 1993:50-72.
43. Katz AM. Excitation-contraction coupling. In: Physiology of the Heart. New York, NY: Raven Press Ltd; 1992:243-273.
44. Lew WYW, Hryshko LV, Bers DM. Dihydropyridine receptors are primarily functional L-type calcium channels in rabbit ventricular myocytes. Circ Res. 1991;69:1139-1145.
45. Beuckelmann DJ, Babauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation. 1992;85:1046-1055.
46. 1 receptor subtype. Circ Res. 1993;73:413-423.
47. 2+ modulation. Circ Res. 1996;78:302-311.
48. 2 receptor subtype in the human atrium. J Mol Cell Cardiol. 1992;28:1789-1799.
49. Zagrosek-Regitz V, Friedel N, Heymann A, Bauer P, Neuß M, Rolfs A, Steffen C, Hildebrandt A, Hetzer R, Fleck E. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation. 1995;91:1461-1471.
50. 2 receptor subtypes in hypertrophied rat hearts. Am J Physiol. 1994;267:H844-H852.
51. Holubarsch C, Hasenfuss G, Schmidt-Schweda S, Knorr A, Pieske B, Ruf T, Fasol R, Just H. Angiotensin I and II exert inotropic effects in atrial but not ventricular human myocardium. Circulation. 1993;88:1228-1237.
52. Cheng CP, Suzuki M, Ohte N, Ohno M, Wang ZM, Little WC. Altered ventricular and myocyte response to angiotensin II in pacing induced heart failure. Circulation. 1996;78:880-892.
53. Lefroy DC, Crake T, Del Monte F, Vescovo G, Dalla Libera L, Harding S, Poole-Wilson PA. Angiotensin II and contraction of isolated myocytes from human, guinea pig, and infarcted rat hearts. Am J Physiol. 1996;39:H2060-H2069.
54. Allen IS, Cohen NM, Dhallan RS, Gaa ST, Lederer WJ, Rogers TB. Angiotensin II increases spontaneous contractile frequency and stimulates calcium current in cultured neonatal rat heart myocytes: insights into mechanisms. Circ Res. 1988;62:524-534.
55. Tsutsui H, Spinale FG, Nagatsu M, Nagatsu M, Schmid PG, Ishihara K, DeFreyte G, Cooper G, Carabello B. The effects of chronic β-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic mitral regurgitation. J Clin Invest. 1994;93:2639-2648.